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ABSTRACT
Aims To evaluate costs, effects and cost-effectiveness of increased reach of specific smoking cessation interventions in
Germany. Design A Markov-based state transition return on investment model (EQUIPTMOD) was used to evaluate
current smoking cessation interventions as well as two prospective investment scenarios. A health-care perspective
(extended to include out-of-pocket payments) with life-time horizon was considered. A probabilistic analysis was used to
assess uncertainty concerning predicted estimates. Setting Germany. Participants Cohort of current smoking popula-
tion (18+ years) in Germany. Interventions Interventions included group-based behavioural support, financial incen-
tive programmes and varenicline. For prospective scenario 1 the reach of group-based behavioral support, financial
incentive programme and varenicline was increased by 1% of yearly quit attempts (= 57915 quit attempts), while
prospective scenario2 representedahigher reach,mirroring the levels observed inEngland.Measurements EQUIPTMOD
considered reach, interventioncost, numberof quitters, quality-of-lifeyears (QALYs)gained,cost-effectivenessandreturnon
investment.Findings Thehighest returns throughreduction in smoking-relatedhealth-care costswere seen for thefinan-
cial incentive programme (€2.71 per €1 invested), followed by that of group-based behavioural support (€1.63 per €1
invested), comparedwith no interventions. Varenicline had lower returns (€1.02 per €1 invested) than the other two inter-
ventions.At thepopulation level,prospective scenario1 led to15034QALYsgainedand€27millioncost-savings, compared
with current investment. Intervention effects and reach contributed most to the uncertainty around the return-on-
investment estimates. At a hypothetical willingness-to-pay threshold of only €5000, the probability of being cost-effective
is approximately 75% for prospective scenario 1. Conclusions Increasing the reach of group-based behavioural support,
financial incentives and varenicline for smoking cessation by just 1% of current annual quit attempts provides a strategy to
German policymakers that improves the population’s health outcomes and that may be considered cost-effective.
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INTRODUCTION
Smoking constitutes a significant risk factor for various
diseases, including cardiovascular disease, stroke, lung
disease, autoimmune disease and cancer [1–3]. Between
2000 and 2050, it is estimated that smoking will have
caused approximately 450 million deaths world-wide
[4]. Based on recent findings this number may even be
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higher, as 17% of excess mortality among smokers may,
falsely, not have been attributed to smoking [5]. In
contrast to males, the mortality rate of lung cancer in
females has been rising in Germany for more than three
decades, with smoking as the biggest risk factor [6,7].
Using survey data, health-related costs of smoking in
Germany have been estimated to amount to more than
€30 billion per year [8]. Thus, tobacco control remains a
fundamental leverage point to improve population health
outcomes [9].
Smoking prevention and cessation are currently the
most effective methods to avoid the detrimental conse-
quences of smoking. Stopping smoking before the ages
of 30 or 40 years has been found to reduce the associ-
ated mortality risk by approximately 97 and 90%, respec-
tively [10]. In countries with a social health-care system
such as Germany, reducing smoking rates and thus the
health consequences also leads to lower health-care
costs, which reduces the burden on society. Smoking
prevention includes discouraging adolescents from
starting smoking, promoting smoke-free environments
and restricting use of and access to tobacco products.
Smoking cessation methods include pharmacotherapy
and behavioural support. However, these interventions
differ in their cost-effectiveness and may also be associ-
ated with unintended consequences. For example, tax
increases may create illicit markets [11,12], while e-
cigarettes may prevent certain smokers from quitting
[13]. Compared with the United Kingdom [14], smoking
cessation aids are used less frequently in Germany
[15,16], while the smoking prevalence (18.0 versus
24.5%) is higher [17,18]. This underlines the need for
more smoking cessation strategies in Germany. In order
to reduce the number of smokers efficiently, decision-
makers must consider the cost-effectiveness of available
programmes.
Thus, the aims of this study are to evaluate incremental
costs, incremental quality-adjusted life years (QALYs),
cost–effectiveness and smoking-related return on invest-
ment (ROI) of increased reach of three smoking cessation
interventions in Germany using the ROI model from the
European study on Quantifying Utility of Investment in
Protection from Tobacco (EQUIPT) [19]. In particular, this
study evaluates two prospective scenarios where the reach
(= number of quit attempts made annually) through
group-based behavioural support, financial incentives
and varenicline is increased by a small (prospective sce-
nario 1) and large (prospective scenario 2) amount, while
all other interventions remain unchanged. This will pro-
vide decision-makers with important information for
future resource allocation decisions. As a secondary goal,
this study also aims to assess the transferability of a




EQUIPTMOD is described in more detail elsewhere in this
issue [20]. It was developed specifically as a decision-
support tool and has a user-friendly interface (front-
end) underpinned by a Markov state transition model
(back-end) [21]. The Markov model has three health
states—current smoker (smokes daily or occasionally),
former smoker and death—and includes four smoking-
attributable diseases [lung cancer, chronic obstructive
pulmonary disease (COPD), stroke and coronary heart
disease]. The model follows a cohort of current smokers
until death and assigns the costs and disutilities through
annual cycles. This allows costs and effects of different
tobacco control interventions to be evaluated from
short-, medium and life-time perspectives. The age of
the German cohort in EQUIPTMOD ranges from 18 to
85 years, and the cohort is followed until the age of
100. As most individuals have died by this point, the
time-frame of the model is a life-time. New patients
are not added to the cohort (i.e. it does not consider
births). The analysis considers primarily a health-care
perspective, but it has been extended to include out-of-
pocket payments that current smokers use to access
cessation services. German legislation treats smoking
cessation interventions as life-style products, and there-
fore does not reimburse the associated costs for pharma-
cotherapy and only partly reimburses costs for
behavioural support. A key feature of the EQUIPTMOD
is that model inputs can be modified (including local
demographics and intervention reach/costs) and the user
is also able to add custom interventions. The model
contains a base case that resembles the current
investment in tobacco control activities for the selected
country. The user is also able to analyse the impact of
prospective changes to the current level of investment
by modifying key model inputs. The predicted results
allow comparisons between the current and prospective
scenarios, as well as with a zero investment scenario,
which includes only indoor smoking bans, brief physi-
cian advice and current levels of tobacco taxation.
Current interventions
Smoking cessation interventions in Germany can be di-
vided into two main groups, behavioural support and
pharmacotherapy. Behavioural support involves primarily
specialist support, which is offered to patients either
individually or in groups. Pharmacotherapy for smoking
cessation in Germany includes medications such as
bupropion, an antidepressant, and varenicline, a partial
nicotine receptor agonist. Varenicline has been shown
to be more cost-effective than bupropion [22] for
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smoking cessation. However, in Germany, over-the-
counter nicotine replacement therapies (NRT) such as
nicotine patches and gums are used significantly more
frequently for smoking cessation than prescription drugs
(approximately 20 versus 1%) [15], although they are
less effective [23,24].
Other interventions for smoking cessation
Incentive programmes, a subgroup of behavioural support,
have been shown to be effective for smoking cessation
[25–27]. Financial incentive programmes promote
smoking cessation by providing financial incentives to quit.
Certain financial incentive programmes have demon-
strated their effectiveness over a 1 year horizon [25,28].
The advantage of financial incentive programmes include
their ease of implementation by companies and insurance
companies. Currently, most statutory insurance companies
in Germany implement reward-based bonus programmes
for smoking cessation [29–31]. However, these bonus
programmes only offer small rewards for participating in
smoking cessation programmes and do not confirm actual
smoking status. E-cigarettes are a relatively new ‘cessation’
intervention. However, long-term data for their effects are
not available.
Current investment and prospective scenarios
The EQUIPTMOD compares current investment with zero
investment by default. Zero investment includes only the
top-level policies (i.e. indoor smoking ban in public places
and tobacco taxes; both at their current levels). In other
words, zero investment represents the theoretical gross
costs of tobacco and is thus the baseline against which
the effects of current and prospective smoking cessation in-
terventions can be evaluated. The current investment in-
cludes all currently implemented smoking cessation
interventions (see Table 1). Moreover, we evaluated how
two additional prospective investment scenarios compare
against the current investment. For prospective scenario
1, the rates of using group-based behavioural support,
financial incentive programmes and varenicline were
increased by 1% of yearly quit attempts, while all other in-
terventions remained unchanged. This 1 percentage point
increase in reach equals 57915 new quit attempts.
Prospective scenario 2 represents a higher utilization case,
where the reach of the three interventionswas increased to
the levels observed in England. The use of the financial
incentive programme, as it is not available in England,
was set to 2.9% to be comparable to the reach of
group-based behavioural support. Results for prospective
scenarios 1 and 2 were calculated for each individual
intervention and as aggregated results for all three inter-
ventions together.
The three interventions (group-based behavioural
support, financial incentive programmes and varenicline)
were chosen because they represent a diverse range of
options available for stakeholders to improve smoking
cessation in Germany. Varenicline represents an effective
pharmacotherapy; group support is a well-accepted and
effective behavioural support and financial incentives
have the potential to improve smoking cessation and can
be implemented in Germany. Varenicline and financial
incentives are currently not reimbursed in Germany, while
group-based behavioural support is partly reimbursed.
Inputs for intervention costs and effectiveness
Model inputs were taken mainly from recent relevant
literature and from the Federal Statistical Office. Detailed
technical documentation is available upon request from
the authors. Inputs used for population, costs and effects
of current interventions are shown in Tables 1 and 2.
Specifically, costs in 2015 for group-based behavioural
support were based on one widely used programme in
Germany. Costs for seven sessions of 90 minutes or three
sessions of 180 minutes and two sessions of telephone
support of 10 minutes [32] are approximately €250. The
Table 1 Demographics, smoking status and intervention reach used for the German cohort.
Absolute population Percentage of total population
Adult population 67 538 844 100
Ex-smokers 13 017 502 19.3
Active smokers 16 547 017 24.5
Absolute attempts and reach per year Percentage of smokers attempting to quit
Yearly quit attempts among active smokers 5 791 456 34.9
Pharmacotherapy reach 688112 11.9
Behavioural support reach 992636 17.1
Combination reach 118146 2.0
No support reach 4 228 921 73.0
A detailed list of input sources is available from the authors. ‘Combination reach’ refers to quit attempts where pharmacotherapy as well as behavioural sup-
port were used; ‘No support reach’ refers to the quit attempts where no aid was used.
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costs for a 12-week standard treatment package (starter +
maintenance) of varenicline were calculated to be €293 in
Germany in 2015 (source: pharmacy pricing). Only
smokers who smoke 10 cigarettes or more were assumed
to be eligible for varenicline, as studies of varenicline effec-
tiveness included only those who smoked 10 or more ciga-
rettes per day.
Although the financial incentive programme and
respective costs are not available in Germany, our
prospective scenarios included its use. Costs of the
financial incentive programme, which required biochem-
ical confirmation of smoking status, were calculated
based on supplementary data from Halpern et al. 2015
[25]. Average costs were calculated to be $235 or
€176 [gross domestic product (GDP)-based purchasing
power parity (PPP)-adjusted, currency year 2015] per
participant of the individual reward group, including a
lump sum cost of €10 per participant for biochemical
testing and laboratory costs. Urinary cotinine immunoas-
say test strips are cheap but reliable alternatives to more
expensive chromatographic methods [33].
The model-based effectiveness of interventions
(likelihood to quit) compared to usual care is shown by risk
ratios (RR) and originate from the Cochrane Database of
Systematic Reviews for group-based behavioural support
and varenicline. The RR for group-based behavioural
support is 1.98 [95% confidence interval (CI) = 1.60,
2.46] [34], the RR for varenicline is 2.27 (95% CI = 2.02,
2.55) [35] and the RR for the individual reward-based
financial incentive programme (using biochemical testing)
after 12months is 2.17 (95% CI = 1.226, 3.851) [25]. We
excluded effectiveness data of cessation studies that were
based solely on self-report and lacked biochemical testing
to reduce possible bias [36].
In Germany the Institute of Quality and Efficiency in
Health Care (IQWiG) conducts health technology assess-
ments on behalf of the German Statutory Health Insurance
and recommends using a discount rate for costs of 3% in its
methodological guidelines [37]. To conduct a more conser-
vative evaluation, all costs but also effects were discounted
by 3% in this study.
Outcomes
Quitters per 1000 smokers, QALYs gained (population
level), the incremental cost effectiveness ratio (ICER)
and the return on investment (ROI) for smoking-related
costs are presented within the Results section. To derive
the ICER, the incremental costs per smoker are divided
by the incremental QALYs per smoker. The resulting
value describes the cost-effectiveness of an intervention
strategy compared to another. The ROI for smoking-
related costs was calculated by dividing the incremental
health-care costs by the incremental investment costs.
Therefore, ROIs greater than 1 indicate that the return
is higher than the investment made. We did not
include the values of health gains in the ROI, as there
is no QALY affordability threshold in Germany which
would allow conversion of health effects into monetary
values. Despite the lack of QALY thresholds, QALYs
are easy to understand and are well accepted in the
Table 2 Intervention reach and treatment cost for current investment, prospective scenario 1 and prospective scenario 2.
Intervention
Current investment Prospective scenario 1 Prospective scenario 2
Reach Cost (€) Reach Cost (€) Reach Cost (€)
Pharmacotherapy
Bupropion 7393 1 583063 7393 1 583 063 7393 1 583 063








Mono-NRT 458 931 145 706 003 458 931 145 706003 458 931 145 706 003
Combo-NRT 183 686 54389 425 183 686 54389 425 183 686 54389 425
Behavioral support
Brief physician advice 261 596 2 417147 261 596 2 417 147 261 596 2 417 147
Individual support 102 364 30197 380 102 364 30197 380 102 364 30197 380








SMS service 82735 1 396567 82735 1 396 567 82735 1 396 567
Self-help material 756 355 9 900687 756 355 9 900 687 756 355 9 900 687
Financial incentives n.a. n.a. 57915 10193 040 167 954 29559 904
Total 1 942 344 259 500 750 2 116089 311 145415 3 028 156 562 617 342
() = numbers in brackets show the percentage increase compared with current investment. Current investment includes all currently implemented smoking
cessation interventions and their respective usage rates and costs in Germany. Prospective scenario 1 increases the usage rates of only group support, financial
incentives and varenicline by 1% (= 57 915) of yearly quit attempts. Prospective scenario 2 increases the reach of group support as well as financial incentives
to 2.90% and to 14.49% for varenicline. NRT = nicotine replacement therapy; n.a. = not available; SMS = short message service.
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scientific community. IQWiG does not exclude the use of
QALYs in their assessments, but has clear standards for
their use [37].
Sensitivity analysis
Both deterministic and probabilistic sensitivity analyses
were performed. The cost-effectiveness planes and the
cost-effectiveness acceptability curves of current invest-
ment, prospective scenarios 1 and prospective scenario 2
versus zero investment were each determined. For each
probabilistic sensitivity analysis, utilities and reach of the
interventions were calculated with a beta distribution; RR
inputs were calculated with a log-normal distribution and
costs with gamma distributions. Based on probabilistic tor-
nado diagrams for incremental QALYs and incremental
costs, inputs contributing most to the variation of results
were determined. Groups of inputs with similar character-
istics were identified and the effects of these groups on
model uncertainty were evaluated by joint probabilistic
variation while leaving other inputs fixed. The examined
input groups included utilities, intervention reach, inter-
vention effects, intervention costs, other non-intervention
costs and relative risks of smoking-attributable diseases.
The results for these inputs were sorted based on the size
of the 95% CI and illustrated in tornado diagrams. The
deterministic sensitivity analyses examined the effect of
various discount rates for both costs and effects on the
outcomes calculated. EQUIPT model version 2.80 was
used. Figures were designed with the software R [38]
version 3.3.0 and the package ggplot2 [39].
RESULTS
Demographics, smoking status and cost
In 2011, the adult population of Germany (18+)
consisted of approximately 67.5 million people [40]. Of
these, approximately 13.0 million were ex-smokers, while
16.5 million were active smokers [40]. Approximately 5.8
million active smokers attempt to quit per year [41]. The
vast majority (73.0%) of these try to quit without support
(Table 1).
Current investment and prospective scenarios
Table 2 shows the intervention reach and costs of the cur-
rent investment, prospective scenarios 1 and 2. In current
investment, varenicline and bupropion were used in fewer
than 1% of quit attempts. Individual behavioural therapy
was used twice as frequently as group-based behavioural
support. Self-help materials and mono-NRT were the most
frequently used of the evaluated interventions. Total costs
calculated for the current investment were approximately
€260 million. In prospective scenario 1, the reach of
group-based behavioural support, the financial incentive
programme and varenicline were increased by 1%
(n = 57915) of overall quit attempts and total costs were
calculated to be €311 million. In prospective scenario 2,
the reach of group-based behavioural support and
varenicline was increased to the published levels for
England. This resulted in an additional 800000 quit
attempts for varenicline and costs, which were approxi-
mately €234 million higher than costs calculated for
varenicline in current investment. In addition, the use of
the financial incentive programme was set to 2.90% to
resemble the use of group-based behavioural support.
Prospective scenario outcomes
Table 3 illustrates the outcomes for both prospective sce-
narios. The zero investment, which considers only effects
of a smoking ban and tobacco taxes at the current level,
led to 17.12 quitters per 1000 smokers and produced a to-
tal of 235434350 QALYs. Compared to zero investment,
current investment led to an additional 55022 QALYs
and resulted in an ICER of €323 per QALY. For prospective
scenario 1, group-based behavioural support alone led to
5142 additional QALYs compared with current invest-
ment. Dividing these QALYs by the number of smokers in
Germany (16547017) resulted in 0.0003 incremental
QALYs gained per smoker. This, combined with incremen-
tal cost savings of –€0.55 per smoker, resulted in
dominance–—more QALYs and lower costs—of group-
based behavioural support in prospective scenario 1 over
current investment. The net ROI was calculated to be
€0.63 (€1.63 – €1). Overall, prospective scenario 1 deliv-
ered 15034 additional QALYs and saved €27133798
(€1.6398 × 16547017). In both prospective scenarios,
all reach increases were dominant. The cost savings and
the ROI were highest for the financial incentive pro-
gramme. In prospective scenario 2, the increased reach of
varenicline by 14.5% of quit attempts added 52104
QALYs. Together, all three interventions in prospective sce-
nario 2 led to a gain of 82709 QALYs and 22 quit attempts
per 1000 smokers (an increase of approximately three in
1000 compared with current investment).
Sensitivity analysis
Probabilistic analyses were used to determine the uncer-
tainty of model input groups for current investment, pro-
spective scenario 1 and 2 compared to zero investment.
Comparing current investment to zero investment, the tor-
nado diagrams (Figs 1 and 2) showed that the intervention
effects and the reach of interventions contributed most to
the uncertainty of aggregated costs and QALYs. Other in-
put groups, such as intervention costs, relative risks and
utilities, had little impact on the results.
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In the multivariate probabilistic sensitivity analysis
(Fig. 3), a clear trend towards fewer costs and better
incremental effectiveness can be observed. While 60.8%
of replications in the current investment analysis (left plot)
showed positive incremental costs, only 57.6% and 53.9%
did so for prospective scenarios 1 (middle plot) and 2 (right
plot), respectively. Overall, 26 replications of the current
investment, 12 replications of prospective scenario 1 and
only three replications of prospective scenario 2 were
dominated. Due to the small incremental effects and costs,
which were calculated per smoker, the upper confidence
interval of prospective scenario 1 appears very steep, but
has an actual slope or ICER of 75000 (north-east
quadrant) and prospective scenario 2 has 38571










per smoker (€)a ICER (€)a ROI (€)a
Zero investment 17.12 235434350b
Current investment 19.05 55022 0.0033 1.08 323.33 0.93
Prospective scenario 1
GBS (1.88%) 19.23 5142 0.0003 – 0.55 – 1770.35c 1.63
FIP (1.0%) 19.26 6039 0.0004 – 1.05 – 2895.33c 2.71
Varenicline (1.66%) 19.18 3775 0.0002 – 0.02 – 77.81c 1.02
All three 19.58 15034 0.0009 – 1.64 – 1809.70c 1.65
Prospective scenario 2
GBS (2.9%) 19.41 10408 0.0006 – 1.11 – 1770.57c 1.63
FIP (2.9%) 19.69 18118 0.0011 – 3.06 – 2887.68c 2.71
Varenicline (14.49%) 20.88 52104 0.0031 – 0.25 – 77,80c 1.02
All three 21.95 82709 0.0050 – 5.16 – 1031.69c 1.29
Outcomes based on lifetime horizon; Euros as absolute values. ‘All three’ depicts cases where reach was increased for all three interventions together. The sum
of incremental quitters per 1000 smokers of single interventions compared with current investment add up to incremental quitters per 1000 smokers for ‘All
three’. aCompared with zero investment for current investment, compared with current investment for prospective scenarios 1 and 2; bcompared with no tax-
ation, no smoking ban, no brief physician advice. GBS = group behavioural therapy; FIP = financial incentive programme; ROI = return on investment;
ICER = on incremental cost-effectiveness; cdominant [cheaper to run but generates more quality-of-life years (QALYs)]. The actual figure (as negative, rather
than just stating ‘Dominant’) is reported here to allow readers to map this figure onto the reported ROI figure.
Figure 1 Incremental costs for current investment
and prospective scenarios versus zero investment,
univariate probabilistic sensitivity analyses for different
selected groups. Note: In the tornado diagram, 95%
confidence intervals are represented by the width of
the horizontal bars
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(north-east quadrant), respectively. The latter is in the
range of commonly observed willingness-to-pay (WTP)
thresholds. Comparing the predicted point estimator
(mean of the model iterations) across current investment
and prospective scenarios 1 (€1222) and 2 (€1061)
showed that it moved further away from the origin into
the south-east quadrant, resembling dominance. The
corresponding cost-effectiveness acceptability curve is
shown in Fig. 4. At aWTP threshold of €15000, the prob-
ability of being cost-effective is around 85% for current in-
vestment, 90% for prospective scenario 1 and 92% for
prospective scenario 2.
Figure 2 Incremental quality-of-life years
(QALYs) for current investment and prospective
scenarios versus zero investment, univariate proba-
bilistic sensitivity analyses for different selected
groups. Note: In the tornado diagram, 95% confi-
dence intervals are represented by the width of
the horizontal bars
Figure 3 Multivariate probabilistic sensitivity analyses of incremental cost-effectiveness ratios for current investment and prospective scenarios ver-
sus zero investment. Note: 1000 replications run in each probabilistic analysis. Predicted point estimator depicted as white cross; 95% confidence in-
terval depicted as dashed lines. Zero investment as reference
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The impact of different discount rates on effects and
cost-effectiveness on current investment and prospective
scenario 1 were examined using deterministic sensitivity
analyses (see Table 4). Current investment was dominant
only at discount rates between 0 and 2.46%, but was not
dominant at higher rates. Prospective scenario 1
was found to be cost-saving for all evaluated discount
rates (0–5%). Additional analysis (Supporting informa-
tion, Appendix S1) revealed that the discount rate of costs
had a stronger qualitative effect on the ICER per QALY
than the discount rate of effects. Furthermore, at a 5%
discount rate, prospective scenario 2 delivered five times
more QALYs compared with prospective scenario 1, but
the ROI for smoking-related costs was approximately
one-third lower (see Supporting information, Appendix
S2 and Table 4).
DISCUSSION
The EQUIPT tool was developed to help stakeholders to
evaluate new and ongoing smoking cessation strategies.
We have evaluated several strategies for Germany using
this model. Our evaluation showed that a scenario with
increased reach of group-based behavioural support, the
financial incentive programme and varenicline resulted in
long-term cost savings and was a dominant (lower costs
and higher QALYs) strategy. When uncertainty was
accounted for, current investment and prospective
scenarios were not dominant, although the incremental
cost per QALY was low. The average incremental QALY
gain per user was relatively small, but was offset by
relatively low intervention costs and avoided disease costs.
Sample iterations for prospective scenarios showed better
cost-effectiveness than for current investment. Overall, we
found that it was possible to adjust and refine a national
tobacco control model developed for England to fit the
German context. This also offered a feasible alternative to
creating a completely new model.
Group-based behavioural support
Group-based behavioural support is currently reimbursed
partly by most statutory health insurances in Germany.
The cost savings per invested Euro are between those of
varenicline and the financial incentive programme. Some
studies [32,42] reported that specific group-based behav-
ioural support programmes are more effective than the ef-
fectiveness value used in our model. However, these studies
did not include control groups and did not confirm
smoking status with biochemical methods, only used but
self-reported status. Furthermore, these effectiveness esti-
mates may be affected by selection bias and possible
reporting bias due to social desirability, and were thus not
incorporated into this evaluation. The use of group-based
behavioural support in Germany is low compared to the
United Kingdom and seems to have decreased further re-
cently. The use of support involving physicians, other
health specialists and clinics fell from 7% in 2012 to 5%
in 2014 [43]. This is unfortunate, as we find that group-
based behavioural support provides good value for money.
The reach of this intervention may be improved by offering
these programmes at the work-place or by increasing
reimbursement.
Figure 4 Cost-effectiveness acceptability curve for current investment
and prospective scenarios versus zero investment. Note: 1000 replica-
tions run in the probabilistic analysis
Table 4 Impact of discount rate on QALYs gained, ICER and
smoking-related ROI of current investment vs. zero investment
and prospective scenario 1 versus current investment,







gained (€) ROI (€)
Current investment versus zero investment
0% 106756 1121.18a 1.44
1% 83491 738.46a 1.23
3% 55022 323.33 0.93
5% 39304 1725.86 0.75
Prospective scenario 1 versus current investment
0% 29193 2220.45a 2.56
1% 22831 2144.04a 2.18
3% 15046 1809.54a 1.65
5% 10748 1259.95a 1.33
ROI = return on investment; ICER = on incremental cost-effectiveness.
aDominant [cheaper to run but generates more quality-of-life years
(QALYs)]. The actual figure (in negative, rather than just stating ‘Domi-
nant’) is reported here to allow readers to map this figure onto the reported
ROI figure.
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Financial incentive programme
The financial incentive programme is a dominant strategy,
and according to our evaluation is the most cost-saving in-
tervention. Deposit-based financial incentive programmes
are even more cost-effective than reward-based
programmes [25], but patients generally refrain from put-
ting their own money at risk. Hence, proposed reach can
often not be achieved for deposit-based financial incentive
programmes. One big advantage of the evaluated financial
incentive programme is that participants are paid only
when they actually stop smoking. This is not true for other
interventions, where money is invested irrespective of
smoking status and success. This also explains the rela-
tively low average cost of financial incentive programmes.
While the full costs for a successful quitter are US$960
(€681, GDP-based PPP-adjusted, currency year 2015),
the average costs for each participant only amount to ap-
proximately US$235 (€167, GDP-based PPP-adjusted,
currency year 2015) [25]. Moreover, financial incentive
programmes can be implemented easily by health insur-
ances and private companies, as no specialist support is
needed. One drawback of financial incentive programmes
is their decreasing effectiveness 3 months after incentives
end [26]. This effect was also observed for financial incen-
tives for weight control in obesity [44]. Halpern et al. 2015
[25] showed that although effectiveness was halved 6
months after stopping incentives, it was still good
(RR= 2.17). As the estimated annual excess costs of
employing a smoker can range around US$5816
(€4482, GDP-based PPP- and inflation-adjusted, currency
year 2015) [45], smoking-related costs are likely to be
higher than financial incentive programme costs, even on
an annual basis [25]. Another risk of financial incentive
programmes is the enrolment of non-smokers. Providers
should be aware of a patient’s or employee’s smoking status
before offering respective programmes, and smoking status
should be confirmed through biochemical testing before
programme initiation.
Varenicline
Varenicline also resulted in cost savings in prospective sce-
narios 1 and 2, but the ROI of approximately €1 was lower
than for group-based behavioural support and financial in-
centive programmes. The increase in reach led to approxi-
mately 0.07 QALYs gained per additional varenicline user.
These 3–4 quality-adjusted weeks seem to be a relatively
weak outcome. This is due mainly to the prerequisite that
only smokers of 10 or more cigarettes per day were as-
sumed to be eligible for varenicline, and thus the model re-
duced the effectiveness accordingly. Nevertheless, the
investment was dominant because the avoided costs were
relatively high. While varenicline offered the best
effectiveness among the three interventions, it was also
the most expensive. Increasing the reach of varenicline to
that observed in the United Kungdom (prospective scenario
2) may not be feasible, as this would lead to an increase in
usage of 2200% comparedwith current levels. An increase
of 1 percentage point in the current reach seems more re-
alistic. One possibility to increase reach for varenicline
would be to lower costs and/or access restrictions [46]. In
contrast to standard NRT, where effectiveness increases
with age, varenicline seems equally effective in younger
and older people [47]. Moreover, in a real-world setting,
varenicline together with specialist behavioural support
was very effective [24,48] and thus offers potential for
transferring this evidence outside study environments.
Sensitivity analysis
To identify the most important drivers of model results, we
performed a univariate probabilistic analysis using tornado
diagrams. The inputs for intervention effects and reach had
the highest impact on both costs and QALYs. Therefore, it
is essential to find high-quality sources for these inputs.
The RRs used in our analyses were derived from interna-
tional randomized controlled trials. At least for the reach,
we were able to identify inputs which reflected specifically
the current situation in Germany. The cost-effectiveness
plane of the current investment versus zero investment
showed that approximately 40% of probability sensitivity
analysis (PSA) iterations were located within the south-
east quadrant, the quadrant which indicates dominance.
This amount increased to 45.7% for prospective scenario
1 and to 47.5% for prospective scenario 2. The majority
of iterations were therefore within the north-east quad-
rant, mainly close to the zero point. The upper boundary
of the 95% CI for the ICERs excluded dominated replica-
tions for both scenarios, and was located close to the y-axis
for prospective scenarios 1 and 2 (Fig. 3). Using exemplary
WTP thresholds of €5000, €10000 and €15000 (as
Germany does not state any threshold) the conservative
prospective scenario 1 had a probability of being cost-
effective of approximately 75, 85 and 90% respectively
(Fig. 4).
Assisted versus unassisted quitting
One general criticism of assisted smoking cessation is that
the vast majority of ex-smokers quit without assistance
[49]. According to the Eurobarometer 2012, 76% of ex-
smokers in the EU27 and 75% of ex-smokers in Germany
quit without assistance [50]. Only approximately 0.8%
seemed to use prescription medication for quit attempts
in Germany [15]. Possibly, many more people would have
quit smoking if they had used smoking cessation interven-
tions. This question requires more research.
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Implications for German stakeholders
This analysis provides information to policy/decision-
makers and wider stakeholders to justify the extent of
health and economic returns that a policy change in cur-
rent tobacco cessation in Germany could generate. The in-
tention to use an economic tool such as the EQUIPTMOD
in policymaking has been examined elsewhere [51]. Over-
all, German stakeholders were less inclined to use a to-
bacco ROI tool compared with stakeholders from other
countries under consideration. Thus, it is important to plan
dissemination strategies that account for factors that facil-
itate or hinder stakeholder acceptance [52]. Close collabo-
ration between expert users and wider stakeholders will
therefore be needed to implement the findings presented
here.
Regulatory and practical implications
The German Pharmaceutical Directive [53] states that
pharmacotherapy for smoking cessation is a life-style prod-
uct, as smoking is a free life-style choice. Thus, these med-
ications are not reimbursed and consumers have to pay out
of their own pocket. Therefore, increasing the use of phar-
macotherapy by increasing reimbursement is not possible
and probably will not be in the near future. A recent court
decision even excluded the reimbursement of pharmaco-
therapy for smoking cessation for patients registered in
disease-management programmes for COPD [54], despite
their seemingly good cost-effectiveness [55]. Unlike phar-
macotherapy, statutory and private health insurances of-
ten reimburse a certain proportion of group-based
behavioural support costs for smoking cessation (source:
clinic correspondence). Financial incentive programmes
would have to be financed by employers or insurance com-
panies. Although deposit-based financial incentive
programmes also exist, as the patient’s own money is par-
tially at stake, participation rates in these programmes are
relatively low [25]. Other ways to increase the reach of
these interventions include improving German medical
students’ knowledge of how to treat smoking [56], but also
to encourage companies to offer respective seminars or fi-
nancial incentives. Intervention usage can only be in-
creased if decision-makers are willing to act and if they
recognize the need for smoking cessation. The smoking
cessation interventions included in our analysis are reason-
able options that policymakers might want to consider.
Study strengths and limitations
A strength of this study is the evaluation of several invest-
ment scenarios involving different smoking cessation inter-
ventions for Germany. Like any other model, EQUIPTMOD
also has limitations (Coyle et al. 2016), and therefore any
weaknesses of the current analysis should be considered
in that context. Although prospective scenarios included
additional within-model costs (e.g. increased cost of
varenicline due to increased reach), we recognize that ex-
tra costs over and above those within-model costs (e.g.
costs of policy change to improve reach of varenicline)
may be necessary to implement the scenarios. Further-
more, the model does not include possible costs or effects
of adverse events of varenicline. However, recent studies
have not shown an adverse safety profile for varenicline
[57–62]. Close collaboration with stakeholders and experts
in the field of smoking cessation both nationally and inter-
nationally allowed us to evaluate interventions for which
no effectiveness data could be identified for Germany. Thus,
our model is the first, to our knowledge, to evaluate the
cost-effectiveness of financial incentive programmes in
Germany. Formissing inputs, Cochrane effectiveness inputs
from a wide range of studies world-wide were used, and
represented rigorous and well-accepted evidence. Some re-
ported but controversial protective effects of smoking, such
as those regarding Parkinson disease [63–71], were not
accounted for in this model. Some diseases attributable to
smoking [5] were also not included in the model, as the
true impact of smoking could not be estimated, and some
interventions available only in the United Kingdom but
not in Germany were also not considered. Another
important limitation concerns PSA. The economic model
was developed primarily to underpin a ROI tool for
decision-making purposes. This objective inevitably
required not only the provision of a simple generalized user
interface (GUI) and granularity of outputs (a number of
ROI metrics), but also subjected us significantly to consider
Microsoft Excel’s own limitations to handle such a large
model. The PSA functionality was therefore restricted to
provide uncertainty estimates for current investment
versus zero investment scenarios. Thus, the current PSA
functionality does not lend itself directly to the evaluation
of uncertainty concerning current policy changes (i.e. pro-
spective investment versus current investment scenarios).
In such cases, indirect comparison may still be performed
by subjecting both current and projective investments to
the baseline (i.e. zero investment scenario). Future updates
of the EQUIPTMOD should consider improving upon this
PSA functionality.
It should be noted that increasing reach for varenicline
or group-based behavioural support does not increase the
reach of those interventions in isolation. Increasing
varenicline reach will also have an impact upon the sub-
population of potential quitters who receive a combination
of varenicline and a behavioural support (and vice versa for
changes to group-based behavioural support). While the
number of smokers affected will be small, it cannot be
asserted that the improvements in outcomes are associated
only with the increase in reach of the individual therapies.
Moreover, the ROI is based on smoking-related costs and
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does not include other costs associated with quitters living
longer. While the health-care costs of increased life-span
are not accounted for, they are generally far into the future
and, through discounting, would have only aminor impact
on results.
CONCLUSION
Increasing the reach of group-based behavioural support,
financial incentives and varenicline for smoking cessation
by just 1% of current annual quit attempts has a 75%
probability of being cost-effective, at a WTP threshold of
only €5000 per QALY. To German policymakers, this
may provide a strategy that is both economically accept-
able and beneficial to the population’s health outcomes.
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